Roctavian (valoctocogene roxaparvovec-rvox) was approved June 29 to reduce bleeding in adults patients with the blood disorder, according to a news release from the San Rafael, Calif.-based drugmaker.
Every year, hemophilia A affects 1 in 5,000 male births, according to the CDC. Because of the rarity of the disorder, the approval was based on a study of about 130 patients. In the trial, the drug reduced annualized bleeding rate in hemophilia A patients, on average, by 52 percent.
The drug’s cost is $2.9 million.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.